-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, UnbyBpKNAs6x0Ggvq1MvxhobSHsCrRT+3YOOczLi5zYvcCBc2UcmhmUvwRX0i7Uw q5JfZ0hieLiiptg/Iz4iyw== 0000927016-00-004421.txt : 20001222 0000927016-00-004421.hdr.sgml : 20001222 ACCESSION NUMBER: 0000927016-00-004421 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20001220 ITEM INFORMATION: FILED AS OF DATE: 20001221 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CURAGEN CORP CENTRAL INDEX KEY: 0001030653 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 061331400 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: SEC FILE NUMBER: 000-23223 FILM NUMBER: 792843 BUSINESS ADDRESS: STREET 1: 555 LONG WHARF DRIVE STREET 2: 11TH FL CITY: NEW HAVEN STATE: CT ZIP: 06511 BUSINESS PHONE: 2034013330 8-K 1 0001.txt FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________ FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ______________ Date of Report (Date of earliest event reported): December 20, 2000 CuraGen Corporation (Exact name of registrant as specified in its charter) Delaware 0-23223 06-1331400 - ------------------ --------------------- --------------------- (State or other (Commission (IRS Employer jurisdiction of File Number) Identification No.) incorporation)
555 Long Wharf Drive, 11th FLOOR New Haven, Connecticut 06511 ------------------------------------ (Address of principal executive offices) (ZipCode) Registrant's telephone number, including area code: (203) 401-3330 ITEM 9. REGULATION FD DISCLOSURE. On December 20, 2000, the Registrant and the Monsanto Company entered into an early stage collaboration to apply the Registrant's functional genomic technologies to discover key genes involved in the growth of crops with improved quality traits. Specifically, scientists will apply the Registrant's integrated genomic technologies to measure gene expression in various strains of corn in order to identify select genes that naturally improve output traits and enhance the development of corn crops with higher nutritional value. 2 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CURAGEN CORPORATION (Registrant) Date: December 20, 2000 By: /s/ David Wurzer ----------------- Executive Vice President and Chief Financial Officer 3 -----END PRIVACY-ENHANCED MESSAGE-----